Full Text
Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

Abstract

Authors

J Amdahl A. Wang M. Thabane M. Amonkar T.E. Delea

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×